ES2124672B1 - Derivados de tetrahidroisoquinolina. - Google Patents

Derivados de tetrahidroisoquinolina.

Info

Publication number
ES2124672B1
ES2124672B1 ES009700190A ES9700190A ES2124672B1 ES 2124672 B1 ES2124672 B1 ES 2124672B1 ES 009700190 A ES009700190 A ES 009700190A ES 9700190 A ES9700190 A ES 9700190A ES 2124672 B1 ES2124672 B1 ES 2124672B1
Authority
ES
Spain
Prior art keywords
sup
lower alkyl
sub
hydrogen
tetrahydroisoquinoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009700190A
Other languages
English (en)
Other versions
ES2124672A1 (es
Inventor
Alexander Alanine
Anne Bourson
Bernd Buttelmann
Gunther Fischer
Neidhart Marie-Paule Heitz
Vincent Mutel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES2124672A1 publication Critical patent/ES2124672A1/es
Application granted granted Critical
Publication of ES2124672B1 publication Critical patent/ES2124672B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de tetrahidroisoquinolina. La presente invención se refiere al empleo de los derivados de la tetrahidroisoquinolina de fórmula general en donde A es arilo R{sup,1 es hidrógeno, hidroxilo, alquilo inferior, alcoxilo inferior, R-CO- ó R-COO-, en donde R es alquilo inferior; R{sup,2 es hidrógeno, alquilo inferior o cicloalquilo R{sup,3 -R{sup,7 son hidrógeno, alquilo inferior, alcoxilo inferior, hidroxilo o R{sup,3 y R{sup,4 tomados conjuntamente son -(CH{sub,2 ){sub,n - o R{sup,6 y R{sup,7 tomados conjuntamente son -OCH{sub,2 O - y n es 3 ó 4, así como también las sales farmacéuticamente aceptables, para la elaboración de medicamentos para el control o tratamiento de enfermedades que representan indicaciones terapéuticas para los bloqueadores específicos del subtipo de receptores NMDA.
ES009700190A 1996-02-03 1997-01-31 Derivados de tetrahidroisoquinolina. Expired - Fee Related ES2124672B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96101553 1996-02-03

Publications (2)

Publication Number Publication Date
ES2124672A1 ES2124672A1 (es) 1999-02-01
ES2124672B1 true ES2124672B1 (es) 1999-11-16

Family

ID=8222462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009700190A Expired - Fee Related ES2124672B1 (es) 1996-02-03 1997-01-31 Derivados de tetrahidroisoquinolina.

Country Status (29)

Country Link
US (2) US5952344A (es)
JP (1) JP3217290B2 (es)
KR (1) KR100229298B1 (es)
CN (1) CN1167762A (es)
AR (1) AR005613A1 (es)
AU (1) AU723586B2 (es)
BR (1) BR9700816A (es)
CA (1) CA2196392A1 (es)
CO (1) CO4761069A1 (es)
CZ (1) CZ29497A3 (es)
DE (1) DE19703985A1 (es)
ES (1) ES2124672B1 (es)
FR (1) FR2744447B1 (es)
GB (1) GB2309642A (es)
HR (1) HRP970060A2 (es)
HU (1) HUP9700273A1 (es)
ID (1) ID15866A (es)
IL (1) IL120100A (es)
IT (1) IT1289621B1 (es)
MA (1) MA24078A1 (es)
NO (1) NO970431L (es)
NZ (1) NZ314130A (es)
PE (1) PE35698A1 (es)
PL (1) PL318256A1 (es)
SG (1) SG55273A1 (es)
TR (1) TR199700071A2 (es)
TW (1) TW427978B (es)
YU (1) YU3997A (es)
ZA (1) ZA97672B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067203A (en) * 1962-12-04 Tetrahybroisqquinoline derivatives
US3217007A (en) * 1965-11-09 Halo- and nitro-substituted phenethyl-z- methyl tetrahydroisoquinolsnes
NL286505A (es) * 1961-12-15
CH418336A (de) * 1962-02-23 1966-08-15 Hoffmann La Roche Verfahren zur Herstellung von Octahydrophenanthridinverbindungen
US3243438A (en) * 1962-02-23 1966-03-29 Hoffmann La Roche Octahydro phenanthridine compounds
US3480714A (en) * 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
US3361767A (en) * 1966-04-04 1968-01-02 American Home Prod 10, 5(epoxymethano)-10, 11-dihydro-5h-dibenzo[a, d]cyclohepten-13-one and derivatives
GB1386076A (en) * 1971-06-03 1975-03-05 Wyeth John & Brother Ltd Isoquinoline derivatives
US3803151A (en) * 1972-08-23 1974-04-09 Bristol Myers Co Synthesis for the preparation of 3-hydroxy-n-alkylisomorphinans
JPS5291868A (en) * 1976-01-26 1977-08-02 Takeda Chem Ind Ltd Indenopyridine derivatives
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
EP0226511B1 (fr) * 1985-12-13 1989-08-02 LABORATOIRE L. LAFON Société anonyme dite: Dérivés de 5-phényl-1,4,5,6-tétrahydropyrimidine, procédé de préparation et utilisation en thérapeutique
DE68910999T2 (de) * 1988-02-19 1994-03-24 Smithkline Beecham Farma 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten.
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
WO1991017156A1 (en) * 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JPH0741481A (ja) * 1993-05-21 1995-02-10 Hokuriku Seiyaku Co Ltd 両性型三環系化合物
US5389638A (en) * 1993-09-10 1995-02-14 Abbott Laboratories Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake inhibitors
US5439915A (en) * 1994-10-20 1995-08-08 American Home Products Corporation Pyrido[3,4-B]indole carboxamide derivatives as serotonergic agents
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof

Also Published As

Publication number Publication date
JPH09221474A (ja) 1997-08-26
AU723586B2 (en) 2000-08-31
KR970061871A (ko) 1997-09-12
HUP9700273A1 (hu) 1999-08-30
MA24078A1 (fr) 1997-10-01
PE35698A1 (es) 1998-07-16
ZA97672B (en) 1997-08-04
ITMI970153A1 (it) 1998-07-28
ES2124672A1 (es) 1999-02-01
CO4761069A1 (es) 1999-04-27
ID15866A (id) 1997-08-14
FR2744447B1 (fr) 2000-09-29
AU1233597A (en) 1997-08-07
TR199700071A2 (tr) 1997-08-21
HRP970060A2 (en) 1998-04-30
CA2196392A1 (en) 1997-08-04
GB9702049D0 (en) 1997-03-19
AR005613A1 (es) 1999-06-23
US5952344A (en) 1999-09-14
CN1167762A (zh) 1997-12-17
FR2744447A1 (fr) 1997-08-08
TW427978B (en) 2001-04-01
IL120100A (en) 2001-01-28
KR100229298B1 (ko) 1999-11-01
NO970431D0 (no) 1997-01-31
JP3217290B2 (ja) 2001-10-09
US6071929A (en) 2000-06-06
CZ29497A3 (en) 1997-08-13
IL120100A0 (en) 1997-04-15
PL318256A1 (en) 1997-08-04
BR9700816A (pt) 1998-07-07
NO970431L (no) 1997-08-04
IT1289621B1 (it) 1998-10-15
YU3997A (sh) 1999-09-27
HU9700273D0 (en) 1997-03-28
SG55273A1 (en) 1998-12-21
DE19703985A1 (de) 1997-10-30
NZ314130A (en) 1998-04-27
GB2309642A (en) 1997-08-06

Similar Documents

Publication Publication Date Title
ES2123829T3 (es) Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
ES2093753T3 (es) Derivados de estireno.
AR020590A1 (es) 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
ES2171109A1 (es) Derivados de 4-fenil-piridina.
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
PA8557001A1 (es) Nuevos derivados de pirrolidina
SV1999000252A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer ref.pc10113abcz
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
MX9300786A (es) Compuestos hipolipidaemicos.
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
ES2149468T3 (es) Derivados de radicicol.
ES2141787T3 (es) Derivados de la 1,2,3,4-tetrahidro-9-acridinamina.
AR035651A1 (es) Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
AR034350A1 (es) Indazoles e indoles fusionados, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento para el tratamiento de glaucoma
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
ES2072263T3 (es) Derivados de 4-aminopiridina.
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
ES2160700T3 (es) Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a.
ES2124672B1 (es) Derivados de tetrahidroisoquinolina.
AR018077A1 (es) Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990201

Kind code of ref document: A1

Effective date: 19990201

FD1A Patent lapsed

Effective date: 20040916